Regulatory T-Cells, FoxP3 and atherosclerosis

Advances in Experimental Medicine and Biology

Volumn 665, Issue , 2009, Pages 106-114

  Entin Meer, Michal ^b   Afek, Arnon ^b   George, Jacob ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; CARDIOVASCULAR RISK; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MATURATION; DISEASE CONTROL; DISEASE COURSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION; ANIMAL; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

MURINAE;

ANIMALS; ATHEROSCLEROSIS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; T-LYMPHOCYTES, REGULATORY;

EID: 77952467955     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1599-3_8     Document Type: Article

References (66)

1. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005 ; 352(16):1685-95.
2. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006 ; 6(7) :508-19. (Pubitemid 43980523)
3. Benagiano M, Azzurri A, Ciervo A, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA 2003; 100(11):6658-63. (Pubitemid 36666637)
4. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Thl) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145(1) :33-43. (Pubitemid 29292698)
5. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006 ; 1:297-329
6. Kleindienst R, Xu Q, Willeit J, et al. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T-lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Patho11993; 142(6):1927-37.
7. Stemme S, Holm J, Hansson GK. T-lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992; 12(2):206-11.
8. Jonasson L, Holm J, Skalli O, et al. Regional accumulations ofT-cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Arte riosclerosis 1986; 6(2) :131-8. (Pubitemid 16024121)
9. van der Wal AC, Das PK, Bentz van de Berg D, et al. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61(2) :166-70. (Pubitemid 19222746)
10. Choi JI, Chung SW;Kang HS, et al. Establishment ofPorphyromonas gingivalis heat-shock-protein-specific T-cell lines from atherosclerosis patients J Dent Res 2002; 81(5) :344-8.
11. Metzler B, Mayr M, Diet rich H, et al. Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65. Arterioscler Thromb Vase Bioi 1999; 19(8):1905-11. (Pubitemid 29379920)
12. Stemme S, Faber B, Holm Jet al. T-lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92(9) :3893-7.
13. Gotsman I, Gupta R, Lichtman AH. The influence of the regulatory T-lymphocytes on atherosclerosis. Arrerioscler Thromb Vase Bioi 2007; 27(12) :2493-5.
14. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114(9):1209-17.
15. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2(1) :46-53. (Pubitemid 37328775)
16. Sakaguchi S. Naturally arising CD4+ regulatory T-cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-62. (Pubitemid 38680433)
17. Miyara M, Sakaguchi S. Natural regulatory T-cells: Mechanisms of suppression. Trends Mol Med 2007; 13(3):108-16. (Pubitemid 46341958)
18. Ronchetti S, Zollo O , Bruscoli S, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T-lymphocyte subpopulations. Eur J Immunol 2004; 34(3) :613-22. (Pubitemid 39255908)
19. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T-cells. Immunity 2004; 21(4) :503-13.
20. Huehn J. Siegmund K. Lehmann JC, et al. Developmental stage, phenotype and migration distinguish naive- and effector/memory-like CD4+ regulatory T-cells J Exp Med 2004; 199(3):303-13. (Pubitemid 38252043)
21. Yurchenko E. Tritt M, Hay V, et al. CCR5-dependent homing of naturally occurring CD4+ regulatory T-cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 2006; 203(11):245 1-60.
22. Apostolou I, Sarukhan A, Klein Let al. Origin of regulatory T-cells with known specificity for antigen. Nat Immunol 2002; 3(8) :756-63.
23. Paust S. Lu L. McCarty N, et al. Engagement of B7 on effector T-cells by regulatory T-cells prevents autoimmune disease. Proc Natl Acad Sci USA 2004; 101(28):10398-403. (Pubitemid 38924937)
24. Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T-cells induce cyrokine deprivation- mediated apoptosis of effector CD4+ T-cells Nat Immunol 2007; 8(12):1353-62.
25. Collison LW; Workman CJ. Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450(7169) :566-9 (Pubitemid 350190247)
26. Li MO. Sanjabi S. Flavell RA. Transforming growth facror-bera controls development, homeostasis and tolerance of T-cells by regulatory T-cell-dependent and -independenr mechanisms. Immunity 2006 ; 25(3):455-71. (Pubitemid 44354214)
27. Marie JC. Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the Tvcell-specific targeting of transforming growth factor-beta receptor. Immunity 2006; 25(3):441-54. (Pubitemid 44354215)
28. Fontenot JD, Gavin MA. Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T-cells. Nat Immunol2003; 4(4) :330-6. (Pubitemid 36432314)
29. Hori S, Nomura T, Sakaguchi S. Control of regulatory T-cell development by the transcription factor Foxp3. Science 2003 ; 299(5609):1057-61. (Pubitemid 36222930)
30. Brunkow ME, Jeffery EW; Hjerrild KA, et al. Disruption of a new forkhead /winged-helix protein. scurfin, results in the fatallymphoproliferative disorder of the scurfy mouse. Nat Genet 2001 ; 27(1) :68-73 (Pubitemid 32044521)
31. Garnbineri E, Torgerson TR. Ochs HD. Immune dysregulation, polyendocrinoparhy, enteropathy and X-linked inheritance (IPEX). A syndrome of systemic autoimmunity caused by mutations of FOXP3. A critical regulator ofT-ceIl homeostasis. Curr Opin Rheumatol2003; 15(4) :430-5 (Pubitemid 36774255)
32. Roncador G. Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T-cells at the single-cell level. Eur J Immunol 2005 ; 35(6):1681-91. (Pubitemid 40862316)
33. Lages CS. Suffia I. Velilla PA, et al. Functional regulatory T-cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 2008; 181(3) :1835-48.
34. Zhou X. jeker LT, Fife BT, et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008 ; 205(9) :1983-91.
35. Curiel TJ. Regulatory T-cell development: Is Foxp3 the decider? Nat Med 2007; 13(3) :250-3 (Pubitemid 46376657)
36. George J, Shoenfeld Y, Hams D. The involvement of beta2-glycoprotein I (beta2-GPI) in human and murine atherosclerosis. J Autoimmun 1999; 13(1) :57-60 (Pubitemid 29367007)
37. Palinski W; Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86(4):1372-6. (Pubitemid 19061548)
38. Xu Q, Luef G. Weimann S et al. Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein-reactive antisera. Arterioscler Thromb 1993; 13(12) :1763-9.
39. George J. Afek A. Gilburd B, et al. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J Am CoIl Cardiol 2001; 38(3):900-5 (Pubitemid 32835770)
40. George J. Hams D, Gilburd B, et al. Adoptive transfer of beta(2)-glycoprotein l-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000; 102(15):1822-7.
41. Zhou X. Nicoletti A. Elhage R, et al. Transfer of CD4(+) T-cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102(24):2919-22.
42. Harats D. Yacov N, Gilburd B, et al. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am CoIl Cardiol 2002; 40(7):1333-8.
43. Maron R. Sukhova G, Faria AM, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106(13):1708-15.
44. van Puijvelde GH. van Es T, van Wanrooij EJ, et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T-cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Bioi 2007; 27(12):2677-83. (Pubitemid 350158922)
45. Almeida AR, Legrand N, Papiernik M, et al. Homeostasis of peripheral CD4+ T-cells : IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T-cell numbers. J Immunol 2002 ; 169(9):4850-60. (Pubitemid 35217148)
46. Zhang SH, Reddick RL, Piedrahita JA, et al. Spontaneous hypercholesterolemiaand arterial lesions in mice lacking apolipoprotein E. Science 1992; 258(5081) :468-71.
47. Mallat Z, Gojova A, Brun Vet al. Induction of a regulatory T-cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003; 108(10):1232-7. (Pubitemid 37099993)
48. Stoll G, Bendszus M. InRammation and atherosclerosis : Novel insights into plaque format ion and destabilization Stroke 2006,37(7):1923-32 (Pubitemid 44297753)
49. Ishibashi S, Goldstein JL, Brown M.S., et al., Massivexanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994; 93(5) :1885-93. (Pubitemid 24143065)
50. Ait-Oufella H, Salomon BL, Pottcaux S, et al. Natural regulatory T-cells control the development of atherosclerosis in mice. Nat Med 2006; 12(2) :178-80. (Pubitemid 43214743)
51. Mor A, Planer D, Luboshirs G, et al. Role of naturally occurring CD4+ CD25+ regulatory T-cells in experimental atherosclerosis. Arrerloscler Thromb Vasc BioI 2007, 27(4) :893-900. (Pubitemid 46606722)
52. Buono C, Pang H, Uchida Y, et al. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004 ; 109(16) :2009-15. (Pubitemid 38544492)
53. Gotsman I, Grabie N, Gupta Ret al. Impaired regulatory Tscell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006; 114(19) :2047-55. (Pubitemid 44706881)
54. Zhang L, Peppel K, Sivashanmugam P, et al. Expression of tumor necrosis factor receptor-I in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc BioI 2007; 27(5) :1087-94. (Pubitemid 46641962)
55. Ben-Shoshan J, Maysel-Auslender S, Mor A, et al. Hypoxia controls CD4+CD25+ regulatory Tcell homeostasis via hypoxia-inducible factor-lalpha. Eur J Immunol 2008, 38(9) :2412-8.
56. Schwartz SM, Galis ZS, Rosenfeld ME, et al. Plaque rupture in humans and mice. Arterioscler Thromb Vasc BioI 2007; 27(4):705-13. (Pubitemid 46606695)
57. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108(15) :1772-8. (Pubitemid 37296082)
58. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108(14) :1664-72. (Pubitemid 37243650)
59. Hosono M, de Boer OJ, van der Wal AC, et al. Increased expression ofT-cell activation markers (CD25, CD26, CD40L and CD69) in atherectorny specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis 2003, 168(1):73-80. (Pubitemid 36555813)
60. van der Wal AC, Piek JJ, de Boer OJ, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 1998; 80( 1):14-8. (Pubitemid 28351112)
61. Mor A, Luboshits G, Planer D, et al. Altered status ofCD4(+)CD25(+) regulatory T-cells in patients with acute coronary syndromes. Eur Heart J 2006, 27(21):2530-7. (Pubitemid 44627295)
62. Sardella G, De Luca L, FrancavillaV, et al. Frequency of naturally-occurring regulatory T-cells is reduced in patients with ST-segment elevation myocardial infarction Thromb Res 2007, 120(4):631-4. (Pubitemid 47094917)
63. de Boer OJ, van der Meer JJ, Teeling P, et al. Low numbers of FOXP3 positive regulatory T-cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2007; 2(1):e779.
64. De Palma R, Del Galdo F, Abbate G, et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque : Evidence for a local, intracoronary immunologic mechanism. Circulation 2006, 113(5) :640-6.
65. Shevach EM. From vanilla to 28 Ravors: Multiple varieties of T regulatory cells. Immunity 2006; 25(2) :195-201. (Pubitemid 44224153)
66. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T-cells. Atherosclerosis 2008, 197(2) :829-39. (Pubitemid 351417882)